Table 3

Model for viral load, ICC(%) = 19.2
Predictor Parameter Estimate (SE) p-value
Intercept 8.1 (1.2) <0.0001
Age at ART Initiation (months) 0.004 (0.005) 0.45
Number of Available Visits Since ART Initiation -0.13 (0.16) 0.33
Gender
  Female 1.3 (0.7) 0.06
  Male (Reference)
Primary Caregiver
  Parent -0.03 (0.4) 0.94
  Other (Reference)
WHO HIV Clinical Stage 0.3 (0.2) 0.15
ART Therapy
  3TC, ZDV, EFV -1.1 (6) 0.05
  Other -0.5 (0.9) 0.61
  3TC, ZDV, NVP (Reference)
Time Post Initiation of ART Therapy (months) -0.6 (0.2) 0.002
Squared Time Post Initiation of ART Therapy (months) 0.02 (0.01) 0.02
Interaction Between Time and Female Gender -0.19 (0.11) 0.08
Interaction Between Squared Time and Female Gender 0.005 (0.004) 0.23
Interaction Between Time and Number of Visits 0.08 (0.03) 0.006
Interaction Between Squared Time and Number of visits -0.003 (0.001) 0.02

Abbreviations: ART Antiretroviral Therapy, 3TC Lamivudine, ZDV Zidovudine, NVP Nevirapine, EFV Efavirenz, WHO World Health Organization.

Barry et al.

Barry et al. BMC Infectious Diseases 2013 13:476   doi:10.1186/1471-2334-13-476

Open Data